Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 10/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | PLG | P00747 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358827 | 0.85 | TMPRSS11D (0.52) | TMPRSS11DF2F10PLG | |
| SCHEMBL7364973 | 0.83 | TMPRSS11D (0.51) | TMPRSS11DF2F10PLG | |
| SCHEMBL8770769 | 0.83 | TMPRSS11D (0.51) | TMPRSS11DF2F10PLG | |
| SCHEMBL6778981 | 0.81 | ACE (0.53) | OPRM1 | |
| SCHEMBL8770799 | 0.79 | F10 (0.55) | TMPRSS11DF2F10 | |
| Hydrochloric Acid SCHEMBL7360853 | 0.78 | DPP4 (0.61) | F2DPP4FAPDPP8DPP9 | |
| SCHEMBL7706395 | 0.77 | ALDH1A1 (0.55) | TMPRSS11DF2DPP4FAPDPP8 | |
| SCHEMBL15251950 | 0.76 | TMPRSS11D (0.48) | TMPRSS11DF2F10PLG | |
| SCHEMBL15366284 | 0.76 | TMPRSS11D (0.48) | TMPRSS11DF2F10PLG | |
| SCHEMBL15366489 | 0.76 | TMPRSS11D (0.59) | TMPRSS11DF2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | TMPRSS11D 26/4885F2 1/4885F10 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.